Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Stoke Therapeutics Inc (STOK)

Stoke Therapeutics Inc (STOK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Stoke Therapeutics to Present at Upcoming Investor Conferences in June Business Wire - Thu May 28, 3:01PM CDT

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 30.02 (-2.88%)
BIIB : 192.99 (-1.54%)
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire - Mon May 18, 3:01PM CDT

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 30.02 (-2.88%)
MarketBeat.com
Stoke Therapeutics Q1 Earnings Call Highlights MarketBeat - Fri May 8, 11:07PM CDT

Stoke Therapeutics (NASDAQ:STOK) said its lead investigational therapy zorevunersen continued to show durable seizure reductions and improvements in measures of cognition and behavior in four-year open-label...

STOK : 30.02 (-2.88%)
Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates Business Wire - Thu May 7, 3:01PM CDT

– New 4-year longitudinal data from the Phase 1/2a open-label extension (OLE) studies provide additional support for the disease-modifying potential of zorevunersen, an investigational medicine for the...

STOK : 30.02 (-2.88%)
BIIB : 192.99 (-1.54%)
Stoke Therapeutics' Mounting Losses May Actually Validate Its Platform Better Than a Profit Would Barchart - Wed May 6, 4:32PM CDT

Barchart Research What to Expect from STOK Earnings STOK Generated May 6, 2026 Current Price $33.28 EPS Estimate $$-0.80 Consensus Rating Strong Buy Average Move 6.37% Stoke Therapeutics' Mounting Losses...

STOK : 30.02 (-2.88%)
Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates Business Wire - Thu Apr 30, 3:01PM CDT

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 30.02 (-2.88%)
BIIB : 192.99 (-1.54%)
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire - Thu Apr 16, 3:01PM CDT

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 30.02 (-2.88%)
Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference Business Wire - Wed Apr 8, 3:01PM CDT

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 30.02 (-2.88%)
BIIB : 192.99 (-1.54%)
Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors Business Wire - Tue Apr 7, 3:01PM CDT

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational...

STOK : 30.02 (-2.88%)
BIIB : 192.99 (-1.54%)
Stoke Therapeutics Faces Mounting Losses as Earnings Loom Barchart - Tue Mar 24, 4:06PM CDT

STOK : 30.02 (-2.88%)

Barchart Exclusives

Costco Just Reported 'Record-Breaking' Gas Sales. COST Stock Is Falling Anyway. Barchart - 1 minute ago
Costco shares are sinking, even though the company posted a strong Q3 performance. Here’s why investors must still practice caution in buying the post-earnings dip in COST stock. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.